Page 143 - علم الأوبئة

‫المﺮاﺟﻊ‬

World Health Organization, Global Burden of Disease (http://www.
who.int/healthinfo/global_burden_disease/en/index.html, accessed
2009).

‫اﻟﻔﺼﻞ اﻟﺘﺎﺳﻊ‬

P. Juni, L. Nartey, S. Reichenbach, R. Sterchi, P. A. Dieppe, and M. Eg-
ger, ‘Risk of cardiovascular events and Rofecoxib: Cumulative meta-
analysis’, Lancet 364 (2004), 2021–9.

C. M. Rembold, ‘Number needed to screen: Development of a statistic for
disease screening’, BMJ 317 (1998), 307–12.

P. Vineis, P. Schulte, and A. J. McMichael, ‘Misconception about the use of
genetic tests in populations’, Lancet 357 (2001), 709–12.

G. Rose, Rose’s Strategy of Preventive Medicine, with a commentary by K.
T. Khaw and M. Marmot (Oxford University Press, 2008).

C. P. Cannon, ‘Can the polypill save the world from heart disease?’, Lancet
373 (2009), 1313-14.

P. Martens and A. J. McMichael, Environmental Change, Climate and
Health: Issues and Research Methods (Cambridge University Press,
2002).

A. McMichael, S. Friel, A. Nyong, and C. Corvalan, ‘Global environmental
change and health: Impacts, inequalities, and the health sector’, BMJ
336 (2008), 191–4.

National Health Service, National Institute for Health and Clinical
Excellence (NICE) (http://www.nice.org.uk/, accessed 2009).

M. F. Drummond, B. O’Brien, G. L. Stoddart, and G. W. Torrance, Methods
for the Economic Evaluation of Health Care Programmes (Oxford Uni-
versity Press, 1997).

143